Total Payments
$10,685
2024 Payments
$153.52
Companies
21
Transactions
80
Medicare Patients
996
Medicare Billing
$242,960
Payment Breakdown by Category
Research$5,562 (52.1%)
Travel$2,699 (25.3%)
Food & Beverage$2,425 (22.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5,562 | 21 | 52.1% |
| Travel and Lodging | $2,699 | 10 | 25.3% |
| Food and Beverage | $2,425 | 49 | 22.7% |
Payments by Type
Research
$5,562
21 transactions
General
$5,124
59 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $5,424 | 24 | $0 (2021) |
| Supernus Pharmaceuticals, Inc. | $2,594 | 16 | $0 (2019) |
| AMAG Pharmaceuticals, Inc. | $1,155 | 7 | $0 (2017) |
| Merz North America, Inc. | $729.81 | 7 | $0 (2019) |
| JAZZ PHARMACEUTICALS INC. | $150.00 | 1 | $0 (2023) |
| Galderma Laboratories, L.P. | $134.77 | 8 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $118.97 | 1 | $0 (2024) |
| Amgen Inc. | $52.07 | 2 | $0 (2018) |
| ACELL, INC. | $48.27 | 1 | $0 (2020) |
| Impax Laboratories, Inc. | $37.39 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $153.52 | 3 | AstraZeneca Pharmaceuticals LP ($118.97) |
| 2023 | $150.00 | 1 | JAZZ PHARMACEUTICALS INC. ($150.00) |
| 2022 | $18.29 | 1 | Galderma Laboratories, L.P. ($18.29) |
| 2021 | $611.09 | 4 | Allergan, Inc. ($594.80) |
| 2020 | $48.27 | 1 | ACELL, INC. ($48.27) |
| 2019 | $2,934 | 26 | Supernus Pharmaceuticals, Inc. ($2,594) |
| 2018 | $2,647 | 32 | Allergan Inc. ($1,861) |
| 2017 | $4,123 | 12 | Allergan Inc. ($2,968) |
All Payment Transactions
80 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/16/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $17.76 | General |
| 06/19/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $16.79 | General |
| 03/06/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $118.97 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/11/2023 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: NEUROLOGY | ||||||
| 11/03/2022 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $18.29 | General |
| 09/18/2021 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $188.97 | General |
| Category: NEUROSCIENCE | ||||||
| 09/17/2021 | Allergan, Inc. | BOTOX (Biological) | Travel and Lodging | In-kind items and services | $236.17 | General |
| Category: NEUROSCIENCE | ||||||
| 09/17/2021 | Allergan, Inc. | BOTOX (Biological) | Travel and Lodging | In-kind items and services | $169.66 | General |
| Category: NEUROSCIENCE | ||||||
| 06/07/2021 | LeMaitre Vascular, Inc. | ANASTOCLIP (Device) | Food and Beverage | Cash or cash equivalent | $16.29 | General |
| Category: ANASTOCLIP | ||||||
| 02/18/2020 | ACELL, INC. | — | Food and Beverage | Cash or cash equivalent | $48.27 | General |
| 12/30/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $14.71 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
| 12/16/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $6.10 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
| 11/22/2019 | Strongbridge US INC. | KEVEYIS (Drug) | Food and Beverage | In-kind items and services | $24.53 | General |
| Category: Neurology | ||||||
| 11/20/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $7.32 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
| 11/20/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $2.84 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
| 11/08/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $7.29 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
| 10/28/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $83.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
| 10/28/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $26.25 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
| 10/21/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $708.28 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
| 10/21/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $240.76 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
| 10/21/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $177.92 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
| 10/21/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $137.18 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
| 10/19/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $114.81 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
| 10/19/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $33.90 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
| 10/15/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $14.64 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | Supernus Pharmaceuticals, Inc. | $2,594 | 16 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $1,992 | 3 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $976.00 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 174 | 419 | $95,400 | $42,684 |
| 2022 | 6 | 302 | 752 | $174,325 | $74,467 |
| 2021 | 8 | 409 | 1,044 | $242,135 | $103,499 |
| 2020 | 4 | 111 | 179 | $55,550 | $22,310 |
Total Patients
996
Total Services
2,394
Medicare Billing
$242,960
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 44 | 202 | $40,400 | $20,137 | 49.8% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 38 | 56 | $28,000 | $9,853 | 35.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 29 | 74 | $7,400 | $4,905 | 66.3% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2023 | 29 | 46 | $11,250 | $4,082 | 36.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 17 | 18 | $5,850 | $2,615 | 44.7% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 17 | 23 | $2,500 | $1,091 | 43.6% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 73 | 160 | $80,000 | $29,345 | 36.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 65 | 298 | $29,800 | $18,017 | 60.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 72 | 194 | $38,850 | $16,789 | 43.2% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2022 | 64 | 71 | $17,750 | $6,538 | 36.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 16 | 17 | $5,525 | $2,856 | 51.7% |
| 99356 | Extended inpatient or observation hospital service, first hour | Facility | 2022 | 12 | 12 | $2,400 | $922.89 | 38.5% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 89 | 227 | $113,500 | $42,303 | 37.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 87 | 268 | $53,600 | $23,680 | 44.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 71 | 311 | $31,100 | $19,117 | 61.5% |
| 99292 | Critical care delivery critically ill or injured patient | Facility | 2021 | 86 | 89 | $22,250 | $8,354 | 37.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 28 | 29 | $9,425 | $4,968 | 52.7% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 18 | 87 | $6,960 | $2,854 | 41.0% |
| 99356 | Prolonged inpatient or observation hospital service, first hour | Facility | 2021 | 18 | 20 | $4,000 | $1,572 | 39.3% |
| 95816 | Measurement and recording of brain wave (eeg) activity, awake and drowsy | Facility | 2021 | 12 | 13 | $1,300 | $650.39 | 50.0% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 41 | 72 | $35,700 | $13,525 | 37.9% |
| 99292 | Critical care delivery critically ill or injured patient | Facility | 2020 | 36 | 41 | $10,250 | $3,899 | 38.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 21 | 30 | $6,000 | $2,666 | 44.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 13 | 36 | $3,600 | $2,219 | 61.7% |
About Dr. David Rosenberg, M.D
Dr. David Rosenberg, M.D is a Neurology healthcare provider based in Los Alamitos, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013959097.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Rosenberg, M.D has received a total of $10,685 in payments from pharmaceutical and medical device companies, with $153.52 received in 2024. These payments were reported across 80 transactions from 21 companies. The most common payment nature is "" ($5,562).
As a Medicare-enrolled provider, Rosenberg has provided services to 996 Medicare beneficiaries, totaling 2,394 services with total Medicare billing of $242,960. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Los Alamitos, CA
- Active Since 06/12/2006
- Last Updated 08/18/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1013959097
Products in Payments
- INTRAROSA (Drug) $1,155
- XEOMIN (Biological) $729.81
- BOTOX (Biological) $594.80
- EPIDIOLEX (Drug) $150.00
- WAINUA (Drug) $118.97
- RYTARY (Drug) $37.39
- Epidiolex (Drug) $33.07
- Aimovig (Biological) $31.23
- KEVEYIS (Drug) $24.53
- OCREVUS (Biological) $24.40
- Gamunex-C (Biological) $23.83
- GOCOVRI (Drug) $23.55
- TECFIDERA (Drug) $22.00
- Fycompa (Drug) $21.90
- ACTHAR (Biological) $17.51
- VERCISE (Device) $17.24
- ACTIVA (Device) $17.03
- ANASTOCLIP (Device) $16.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Los Alamitos
Dr. Nirav Patel, M.d, M.D
Neurology — Payments: $848,036
Neurology $848,036
Dr. Omid Omidvar, M.d, M.D
Neurology — Payments: $33,376
Neurology $33,376
Dr. Nima Ramezan Arab, M.d, M.D
Neurology — Payments: $6,841
Neurology $6,841
Yamin Shwe, Md, MD
Neurology — Payments: $4,909
Neurology $4,909
Alan Cohen, M.d, M.D
Neurology — Payments: $3,717
Neurology $3,717
Dr. Mohan Tadikonda, M.d, M.D
Neurology — Payments: $247.80
Neurology $247.80